Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 22, 2016 09:43 ET | Source: NeuroDerm Ltd.

NeuroDerm Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

REHOVOT, Israel, Dec. 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
December 22, 2016 07:00 ET | Source: NeuroDerm Ltd.

NeuroDerm Announces Completion of Patient Enrollment and Treatment in a Phase II Trial of ND0612H for Advanced Parkinson’s Disease

- First evaluation of clinical efficacy of ND0612H in advanced Parkinson's patients -REHOVOT, Israel, Dec. 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage...
December 12, 2016 10:38 ET | Source: NeuroDerm Ltd.

NeuroDerm Announces Closing of a Follow-On Offering of Ordinary Shares

REHOVOT, Israel, Dec. 12, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
December 07, 2016 08:50 ET | Source: NeuroDerm Ltd.

NeuroDerm Announces Pricing of a Follow-On Offering of Ordinary Shares

REHOVOT, Israel, Dec. 07, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
December 06, 2016 16:14 ET | Source: NeuroDerm Ltd.

NeuroDerm Announces Launch of a Follow-On Offering of Ordinary Shares

REHOVOT, Israel, Dec. 06, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
December 05, 2016 06:30 ET | Source: NeuroDerm Ltd.

NeuroDerm to Replace Two Phase 3 Clinical Trials with Small Pharmacokinetic Trials Following FDA Meeting on ND0612 Regulatory Development

- Company to pursue comparative bioavailability regulatory route instead of clinical efficacy development route -- NeuroDerm to add patients to its long-term safety trial -- Conference call and...
December 02, 2016 07:00 ET | Source: NeuroDerm Ltd.

NeuroDerm Announces Top-Line Results of Pilot PK Trial Comparing ND0701 with Commercial Apomorphine

REHOVOT, Israel, Dec. 02, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical Company developing drugs for central nervous system (CNS) disorders, today...
November 10, 2016 07:00 ET | Source: NeuroDerm Ltd.

NeuroDerm Announces Third Quarter 2016 Financial Results

REHOVOT, Israel, Nov. 10, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
November 03, 2016 07:00 ET | Source: NeuroDerm Ltd.

NeuroDerm CEO to Present at Upcoming Investor Conferences

REHOVOT, Israel, Nov. 03, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
November 01, 2016 07:00 ET | Source: NeuroDerm Ltd.

NeuroDerm to Host Third Quarter 2016 Financial Results Conference Call on November 10, 2016

REHOVOT, Israel, Nov. 01, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...